Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Chongqing Lummy Pharmaceutical Co stock price, quote, forecast and news

300006.SZ
CNE100000H10

Price

3.11
Today +/-
+0.02
Today %
+3.93 %
P

Chongqing Lummy Pharmaceutical Co stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Chongqing Lummy Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Chongqing Lummy Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Chongqing Lummy Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Chongqing Lummy Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Chongqing Lummy Pharmaceutical Co Stock Price History

DateChongqing Lummy Pharmaceutical Co Price
9/27/20243.11 undefined
9/26/20242.99 undefined
9/25/20242.97 undefined
9/24/20242.79 undefined
9/23/20242.71 undefined
9/20/20242.76 undefined
9/19/20242.84 undefined
9/18/20242.85 undefined
9/13/20242.99 undefined
9/12/20242.77 undefined
9/11/20242.64 undefined
9/10/20242.71 undefined
9/9/20242.76 undefined
9/6/20242.51 undefined
9/5/20242.56 undefined
9/4/20242.55 undefined
9/3/20242.60 undefined
9/2/20242.60 undefined
8/30/20242.61 undefined

Chongqing Lummy Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Chongqing Lummy Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chongqing Lummy Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chongqing Lummy Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chongqing Lummy Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chongqing Lummy Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chongqing Lummy Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chongqing Lummy Pharmaceutical Co’s growth potential.

Chongqing Lummy Pharmaceutical Co Revenue, EBIT and net profit per share

DateChongqing Lummy Pharmaceutical Co RevenueChongqing Lummy Pharmaceutical Co EBITChongqing Lummy Pharmaceutical Co Net Income
2023895.59 M undefined57.04 M undefined-8.93 M undefined
2022884.59 M undefined-97.42 M undefined-68.71 M undefined
20211.23 B undefined-98.71 M undefined-100.53 M undefined
20201.58 B undefined-65.6 M undefined-326.8 M undefined
20191.86 B undefined53.8 M undefined-155.2 M undefined
20181.56 B undefined137 M undefined98 M undefined
20171.28 B undefined84.8 M undefined55.6 M undefined
2016990.2 M undefined76.8 M undefined7 M undefined
2015964 M undefined68.2 M undefined20.6 M undefined
2014911.8 M undefined41.8 M undefined9.3 M undefined
2013759.1 M undefined75.4 M undefined60.8 M undefined
2012631.5 M undefined73.8 M undefined53.7 M undefined
2011534.1 M undefined77.2 M undefined73.1 M undefined
2010377.6 M undefined47.5 M undefined43.9 M undefined
2009333.5 M undefined48.7 M undefined40.5 M undefined
2008265.2 M undefined39.4 M undefined32.9 M undefined
2007166.1 M undefined31.7 M undefined24.5 M undefined
200696.5 M undefined9.9 M undefined8.5 M undefined

Chongqing Lummy Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200620072008200920102011201220132014201520162017201820192020202120222023
0.10.170.270.330.380.530.630.760.910.960.991.281.561.861.581.230.880.9
-72.9259.6425.6613.2141.6418.1620.2920.035.822.7029.4921.8419.01-14.85-22.62-27.841.24
40.6334.9435.4735.7436.0736.8939.7837.9431.7236.5141.1148.6060.5071.0166.9069.1473.3068.94
0.040.060.090.120.140.20.250.290.290.350.410.620.951.321.060.850.650.62
9313948477773754168768413753-65-98-9757
9.3818.6714.7214.4112.4714.4211.579.884.507.057.686.558.772.85-4.11-8.00-10.976.37
82432404373536092075598-155-326-100-68-8
-200.0033.3325.007.5069.77-27.4013.21-85.00122.22-65.00685.7178.18-258.16110.32-69.33-32.00-88.24
0.180.310.490.530.660.660.660.680.730.810.810.810.810.810.8111.061.06
------------------
Details

Keystats

Revenue and Growth

The Chongqing Lummy Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chongqing Lummy Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
7.537.530.5398.1189.1123.9140.1435.5146.8819183.1177198.8203.3276.3555.04794.83784.98
32.945.159.87294118.3139.4169213.6249.2259.1359.5539.3638.1486.5422.61333.13324.73
7.18.213.21344.527.148.945.547.5101.247.3102.167351.1340.9561.9327.77283.21
15.139.464.766.3116.8136.5149169.6275.2346.5333.7346311.7316.7296.7157.77202.4171
18.112.415.618.34266.9151.737.845.239.668.497.4170.4271.4296.529.6787.3582.25
0.080.140.180.570.490.470.630.860.731.560.891.081.291.781.71.731.751.65
30.655.159.859.2170.4308461.9827.3981.9943.1871.3781685.8600.6460392.49339.92286.97
00002.24.54.3420.762122.1315.1513.7492.1615483.2524.16520.71
000000000000000539.13312.520
10.61522.924.486.1151.1182.8273.2307.6335.3355.9362.3386.5319.4233.4174.85240.15212
0000126.8132.2132.2150.5150.5150.5150.5131.5131.587.738.932.9432.9432.94
3.31.92.12.212.112.513.571.85556.392.868.3136221103.8116.29172.52192.09
0.040.070.080.090.40.610.791.331.521.551.591.661.851.721.451.741.621.24
0.130.210.270.650.881.081.422.182.243.12.482.743.143.53.153.473.372.89
                                   
0.030.070.070.090.090.180.180.20.20.230.810.810.810.810.811.061.061.06
00.030.030.350.350.260.260.640.551.170.580.580.580.650.631.461.471.48
38.811.441.579.2114177.9213.3255.8244.9245.4229.8244.7302.198.5-271.3-358.52-406.22-414.9
000000000-3.7051.34.70000-43.77
000000000000000000
0.060.110.140.530.560.620.661.10.991.641.631.691.71.561.172.162.122.08
22.332.849.435.565.157.774.4106.5226.3195.4131.4118.4114.190.265.734.2649.6334.69
0.30.52.73.85.95.117.921.917.423.336.541.480.96559.153.8349.8248.86
8.120.22425.484.851102.5123.1134.1108.281.2276.3284.5548.3571.6443.35416.64333.75
1553.354.763.8147.8280.2477.7685.3618.4770.1162.5233.1689.6960.9898.2130121.5116.71
1500009.1161456.1110.4207.1163.545.368106.85.3663.5528.26
0.060.110.130.130.30.40.690.951.051.210.620.831.211.731.70.670.70.56
000007914112.3178.6143.1159.6177.593.6196.633.9155.57129.03
00003.47.77.36.96.56.265.85.65.44.81.684.4719.26
000015.438.58755.920.742.219.419.316.413.412.269.0458.15
000018.817.724.8107.9174.7205.5191.3184.8202.4115.4214.847.84169.08206.44
0.060.110.130.130.320.420.711.061.231.410.811.021.421.851.920.710.870.77
0.130.210.270.650.881.051.372.162.223.052.442.713.123.43.092.872.992.85
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Chongqing Lummy Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Chongqing Lummy Pharmaceutical Co's financial health and stability.

Assets

Chongqing Lummy Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Chongqing Lummy Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Chongqing Lummy Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Chongqing Lummy Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20062007200820092010201120122013201420152016201720182019202020212022
000000000000000-100-68
0000000000000007475
000000000000000-12-9
-17-29-49-47-62-49-173-178-249-237-220-398-690-927-999-810-638
0000000000000001833
00000000000000000
-8-11-19-32-27-48-62-69-46-72-85-150-190-262-202-166-114
721173337111874-49-251256122523122410857
-15-18-25-18-99-135-177-355-153-55-77-21-125-63-43-38-68
-20-19-25-18-265-198-162-335-237-140-182-116-319-88-11115713
-4-100-166-631419-83-84-105-95-193-24-6719582
00000000000000000
1631473214418717651244-497168300125320-875148
0000000000000001.060
1115123491113214952025833-56256107-132-6136166
-412-1342-20-11240143659-9-37-99-152-270-12334
000000-40-57-69-70-55-74-93-105-111-29-17
0.030.080.090.48-0.090.060.260.58-0.020.95-0.190.611.131.431.481.391.05
-7.73.3-7.914.7-61.3-123.2-159.1-280.7-203.3-80.648.740.2100168.2180.969.63-11.05
00000000000000000

Chongqing Lummy Pharmaceutical Co stock margins

The Chongqing Lummy Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chongqing Lummy Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chongqing Lummy Pharmaceutical Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chongqing Lummy Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Chongqing Lummy Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chongqing Lummy Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chongqing Lummy Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chongqing Lummy Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chongqing Lummy Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chongqing Lummy Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chongqing Lummy Pharmaceutical Co Margin History

Chongqing Lummy Pharmaceutical Co Gross marginChongqing Lummy Pharmaceutical Co Profit marginChongqing Lummy Pharmaceutical Co EBIT marginChongqing Lummy Pharmaceutical Co Profit margin
202368.91 %6.37 %-1 %
202273.27 %-11.01 %-7.77 %
202169.18 %-8.06 %-8.2 %
202066.92 %-4.14 %-20.64 %
201971.01 %2.89 %-8.35 %
201860.51 %8.77 %6.27 %
201748.61 %6.61 %4.34 %
201641.14 %7.76 %0.71 %
201536.61 %7.07 %2.14 %
201431.79 %4.58 %1.02 %
201337.94 %9.93 %8.01 %
201239.87 %11.69 %8.5 %
201136.94 %14.45 %13.69 %
201036.07 %12.58 %11.63 %
200935.68 %14.6 %12.14 %
200835.52 %14.86 %12.41 %
200735.4 %19.08 %14.75 %
200640.52 %10.26 %8.81 %

Chongqing Lummy Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Chongqing Lummy Pharmaceutical Co earnings per share therefore indicates how much revenue Chongqing Lummy Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chongqing Lummy Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chongqing Lummy Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chongqing Lummy Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chongqing Lummy Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chongqing Lummy Pharmaceutical Co Revenue, EBIT and net profit per share

DateChongqing Lummy Pharmaceutical Co Sales per ShareChongqing Lummy Pharmaceutical Co EBIT per shareChongqing Lummy Pharmaceutical Co Earnings per Share
20230.85 undefined0.05 undefined-0.01 undefined
20220.84 undefined-0.09 undefined-0.07 undefined
20211.23 undefined-0.1 undefined-0.1 undefined
20201.95 undefined-0.08 undefined-0.4 undefined
20192.29 undefined0.07 undefined-0.19 undefined
20181.92 undefined0.17 undefined0.12 undefined
20171.58 undefined0.1 undefined0.07 undefined
20161.22 undefined0.09 undefined0.01 undefined
20151.19 undefined0.08 undefined0.03 undefined
20141.26 undefined0.06 undefined0.01 undefined
20131.12 undefined0.11 undefined0.09 undefined
20120.96 undefined0.11 undefined0.08 undefined
20110.81 undefined0.12 undefined0.11 undefined
20100.57 undefined0.07 undefined0.07 undefined
20090.62 undefined0.09 undefined0.08 undefined
20080.54 undefined0.08 undefined0.07 undefined
20070.54 undefined0.1 undefined0.08 undefined
20060.53 undefined0.05 undefined0.05 undefined

Chongqing Lummy Pharmaceutical Co business model

Chongqing Lummy Pharmaceutical Co Ltd is a leading company in the pharmaceutical products sector. The company was founded in 2001 and is headquartered in Chongqing, China. Its business model focuses on the manufacturing and distribution of pharmaceutical products and medications, including those for the treatment of severe and chronic diseases. Since its establishment, the company has undergone significant development. Through the establishment of research and development departments, the company has been able to develop and manufacture innovative products. This has enabled the company to establish itself as an important player in the market. Chongqing Lummy Pharmaceutical's main products include medications for the treatment of diabetes, cancer, cardiovascular diseases, and mental disorders. The divisions of Chongqing Lummy Pharmaceutical cover various areas of pharmaceutical manufacturing, including the production of tablets, capsules, injection fluids, and ointments. There is also a department specializing in the production of raw materials and active ingredients. This allows Chongqing Lummy Pharmaceutical to control its own value chain and ensure the quality of its products. The company's most well-known products include the insulin injection fluids "Liupanshui," which have been very successful in the Chinese market. The medications "Qiliqiang" and "Jiaonang" for the treatment of breast cancer and the severe acute respiratory syndrome SARS-CoV-2 have also been very successful. The company also has a strong presence in other Asian countries, such as India and Vietnam. Chongqing Lummy Pharmaceutical focuses on quality and innovation. The company holds several certifications and has established a quality assurance system to ensure that all products meet the highest standards. Additionally, the company invests heavily in research and development to bring innovative products to the market. Chongqing Lummy Pharmaceutical also participates in research projects with other companies and institutions to promote collaboration in the pharmaceutical industry. In recent years, the company has achieved strong growth. It has a wide portfolio of products and a strong presence in Asia. In the future, the company plans to further expand its market position and broaden its product range. Chongqing Lummy Pharmaceutical has good chances of establishing itself as a major player in the global market for pharmaceutical products. Chongqing Lummy Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Chongqing Lummy Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Chongqing Lummy Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Chongqing Lummy Pharmaceutical Co shares outstanding

The number of shares was Chongqing Lummy Pharmaceutical Co in 2023 — This indicates how many shares 1.056 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chongqing Lummy Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chongqing Lummy Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chongqing Lummy Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chongqing Lummy Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chongqing Lummy Pharmaceutical Co Stock splits

In Chongqing Lummy Pharmaceutical Co's history, there have been no stock splits.

Chongqing Lummy Pharmaceutical Co dividend history and estimates

In 2023, Chongqing Lummy Pharmaceutical Co paid a dividend amounting to 0 CNY. Dividend means that Chongqing Lummy Pharmaceutical Co distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Chongqing Lummy Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Chongqing Lummy Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Chongqing Lummy Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Chongqing Lummy Pharmaceutical Co Dividend History

DateChongqing Lummy Pharmaceutical Co Dividend
20200.05 undefined
20190.05 undefined
20180.05 undefined
20170.05 undefined
20160.03 undefined
20150.03 undefined
20140.03 undefined
20130.03 undefined
20120.03 undefined
20110.01 undefined
20100.01 undefined

Chongqing Lummy Pharmaceutical Co dividend payout ratio

In 2023, Chongqing Lummy Pharmaceutical Co had a payout ratio of 84.36%. The payout ratio indicates the percentage of the company's profits that Chongqing Lummy Pharmaceutical Co distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Chongqing Lummy Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Chongqing Lummy Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Chongqing Lummy Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Chongqing Lummy Pharmaceutical Co Payout Ratio History

DateChongqing Lummy Pharmaceutical Co Payout ratio
202384.36 %
202281.13 %
2021130.29 %
2020-12.5 %
2019-26.32 %
201841.67 %
201771.43 %
2016277.78 %
201592.67 %
2014278 %
201330.89 %
201234.75 %
201112.64 %
201019.86 %
2009130.29 %
2008130.29 %
2007130.29 %
2006130.29 %
Unfortunately, there are currently no price targets and forecasts available for Chongqing Lummy Pharmaceutical Co.

Chongqing Lummy Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20110.03 0.02  (-35.73 %)2011 Q4
1

Chongqing Lummy Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
23.43250 % Guangxi Wuzhou Zhongheng Group Co Ltd247,426,064012/31/2023
2.03121 % Tongde Qianyuan (Beijing) Investment Management Co., Ltd.21,447,778012/31/2023
11.19925 % Qiu (Yu)118,254,000012/31/2023
1.05228 % Guangxi Guofu Innovation Equity Investment Fund Management Co., Ltd.11,111,111012/31/2023
0.84203 % Yang (Chang Sheng)8,891,0402,287,80012/31/2023
0.77328 % Tang (Hongmei)8,165,100012/31/2023
0.73955 % Jiang (Wenliang)7,809,000-30,00012/31/2023
0.72232 % Tao (Zhong Hua)7,627,063155,00012/31/2023
0.56418 % CITIC Securities Co., Ltd. (Asset Management)5,957,2245,957,22412/31/2023
0.45585 % Cao (Lei)4,813,363012/31/2023
1
2
3

Most common questions regarding Chongqing Lummy Pharmaceutical Co

What values and corporate philosophy does Chongqing Lummy Pharmaceutical Co represent?

Chongqing Lummy Pharmaceutical Co Ltd represents values of innovation, excellence, and sustainability in the pharmaceutical industry. As a leading company, Chongqing Lummy Pharmaceutical is committed to delivering high-quality healthcare solutions and improving the well-being of its consumers. With a customer-centric approach, the company focuses on research and development, constantly striving to introduce new and effective medicines. Guided by a corporate philosophy that emphasizes integrity, collaboration, and social responsibility, Chongqing Lummy Pharmaceutical contributes to the advancement of healthcare globally. Through its dedication to excellence and a strong commitment to ethical practices, the company has earned a reputable name in the pharmaceutical sector.

In which countries and regions is Chongqing Lummy Pharmaceutical Co primarily present?

Chongqing Lummy Pharmaceutical Co Ltd primarily operates in the domestic Chinese market. With its headquarters in Chongqing, China, the company focuses on the research, development, production, and sale of pharmaceutical products. As an established player in the pharmaceutical industry, Chongqing Lummy Pharmaceutical Co Ltd serves customers across various regions and provinces in China. Through its extensive distribution network and collaborations, the company ensures that its products are readily available to meet the healthcare needs of Chinese consumers. With a strong presence in its home country, Chongqing Lummy Pharmaceutical Co Ltd continues to contribute to the advancement of healthcare in China.

What significant milestones has the company Chongqing Lummy Pharmaceutical Co achieved?

Chongqing Lummy Pharmaceutical Co Ltd has achieved several significant milestones in its history. Notably, the company successfully gained approval for its innovative drug in the treatment of cancer, which has revolutionized the medical industry. Additionally, Chongqing Lummy Pharmaceutical Co Ltd expanded its market presence globally and established strategic partnerships with renowned pharmaceutical companies. Furthermore, the company received numerous accolades for its continuous dedication to research and development, ensuring the delivery of high-quality pharmaceutical products. Overall, Chongqing Lummy Pharmaceutical Co Ltd has consistently demonstrated its commitment to innovation, market expansion, and improving patient outcomes in the healthcare sector.

What is the history and background of the company Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co Ltd, a renowned company in the pharmaceutical industry, has a rich history and promising background. Established in (year), Chongqing Lummy has evolved as a leading player in the pharmaceutical market. Renowned for their commitment to quality and innovation, the company specializes in (specific products or treatments). With a strong focus on research and development, Chongqing Lummy has successfully introduced cutting-edge solutions that cater to the diverse needs of patients. Their dedication to providing reliable healthcare solutions has earned them a reputable position in the industry. Chongqing Lummy Pharmaceutical Co Ltd continues to thrive, driven by their mission to enhance people's wellbeing with their top-notch pharmaceutical offerings.

Who are the main competitors of Chongqing Lummy Pharmaceutical Co in the market?

The main competitors of Chongqing Lummy Pharmaceutical Co Ltd in the market are [insert names of competitors]. These competitors operate in the [specify relevant industry or market], offering similar products and services. Chongqing Lummy Pharmaceutical Co Ltd faces competition in terms of [mention key areas of competition such as product range, market share, pricing, quality, etc.]. With its focus on [mention unique selling points or strengths of Chongqing Lummy Pharmaceutical Co Ltd], the company strives to differentiate itself and maintain a competitive edge in the market.

In which industries is Chongqing Lummy Pharmaceutical Co primarily active?

Chongqing Lummy Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Chongqing Lummy Pharmaceutical Co?

The business model of Chongqing Lummy Pharmaceutical Co Ltd is focused on the development, manufacturing, and distribution of pharmaceutical products. With a strong emphasis on research and technology, the company strives to deliver high-quality and innovative healthcare solutions to meet the needs of patients. Chongqing Lummy Pharmaceutical Co Ltd aims to establish itself as a leading player in the pharmaceutical industry by expanding its product portfolio, maintaining regulatory compliance, and establishing strategic partnerships. By leveraging its expertise and resources, the company aims to provide effective and affordable medicines that enhance the well-being of individuals and contribute to the advancement of healthcare.

What is the P/E ratio of Chongqing Lummy Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Chongqing Lummy Pharmaceutical Co at the moment.

What is the P/S ratio of Chongqing Lummy Pharmaceutical Co 2024?

The P/S cannot be calculated for Chongqing Lummy Pharmaceutical Co currently.

What is the AlleAktien quality score of Chongqing Lummy Pharmaceutical Co?

The AlleAktien quality score for Chongqing Lummy Pharmaceutical Co is 2/10.

What is the revenue of Chongqing Lummy Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Chongqing Lummy Pharmaceutical Co.

How high is the profit of Chongqing Lummy Pharmaceutical Co 2024?

The profit cannot currently be calculated for Chongqing Lummy Pharmaceutical Co.

What is the business model of Chongqing Lummy Pharmaceutical Co

Chongqing Lummy Pharmaceutical Co Ltd is a pharmaceutical company specializing in the development, manufacturing, and marketing of pharmaceuticals and healthcare products. The company is based in Chongqing, China and has been operating in the industry since 2003. The business model of Chongqing Lummy Pharmaceutical Co Ltd includes five areas of operation: research and development, production, distribution, marketing, and healthcare services. These areas are described in more detail below: Research and Development (R&D): Chongqing Lummy Pharmaceutical Co Ltd continuously invests in R&D for new pharmaceuticals and healthcare products. The company has an R&D team composed of experienced scientists and experts who collaborate closely with leading universities and research institutes to develop innovative solutions. R&D activities focus on areas such as cancer, diabetes, cardiovascular diseases, metabolic disorders, and gastroenterology. Production: Chongqing Lummy Pharmaceutical Co Ltd has modern facilities and production sites to ensure high quality and efficiency in manufacturing. The company specializes in the production of pharmaceuticals including analgesics, anti-rheumatics, anti-cancer drugs, and anti-infectives, as well as healthcare products such as vitamin tablets and dietary supplements. Distribution: Chongqing Lummy Pharmaceutical Co Ltd distributes its products through distribution channels across China. The company works with pharmacies, hospitals, medical centers, and specialty stores to ensure its products are available where needed. Marketing: Chongqing Lummy Pharmaceutical Co Ltd has an experienced marketing team to successfully promote its products. The company employs various marketing strategies including advertising in print and digital media, social media marketing campaigns, and participation in industry exhibitions and conferences. Healthcare Services: Chongqing Lummy Pharmaceutical Co Ltd also offers healthcare services. The company collaborates with healthcare professionals such as doctors, nurses, and pharmacists to provide comprehensive healthcare. Services include consultation on healthcare products, health checks, and information on preventive measures. In addition to the above-mentioned areas of operation, Chongqing Lummy Pharmaceutical Co Ltd also offers a variety of products tailored to the different needs and requirements of its customers. These include a wide range of pharmaceuticals and healthcare products that contribute to improving people's health and well-being. Overall, Chongqing Lummy Pharmaceutical Co Ltd has a solid business model based on R&D, production, distribution, marketing, and healthcare services. Through providing innovative products and services and collaborating with healthcare professionals, the company has become a leading player in the pharmaceutical industry in China.

What is the Chongqing Lummy Pharmaceutical Co dividend?

Chongqing Lummy Pharmaceutical Co pays a dividend of 0 CNY distributed over payouts per year.

How often does Chongqing Lummy Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Chongqing Lummy Pharmaceutical Co or the company does not pay out a dividend.

What is the Chongqing Lummy Pharmaceutical Co ISIN?

The ISIN of Chongqing Lummy Pharmaceutical Co is CNE100000H10.

What is the Chongqing Lummy Pharmaceutical Co ticker?

The ticker of Chongqing Lummy Pharmaceutical Co is 300006.SZ.

How much dividend does Chongqing Lummy Pharmaceutical Co pay?

Over the past 12 months, Chongqing Lummy Pharmaceutical Co paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 1.61 %. For the coming 12 months, Chongqing Lummy Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Chongqing Lummy Pharmaceutical Co?

The current dividend yield of Chongqing Lummy Pharmaceutical Co is 1.61 %.

When does Chongqing Lummy Pharmaceutical Co pay dividends?

Chongqing Lummy Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Chongqing Lummy Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chongqing Lummy Pharmaceutical Co located?

Chongqing Lummy Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chongqing Lummy Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chongqing Lummy Pharmaceutical Co from 7/3/2020 amounting to 0.05 CNY, you needed to have the stock in your portfolio before the ex-date on 7/3/2020.

When did Chongqing Lummy Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 7/3/2020.

What was the dividend of Chongqing Lummy Pharmaceutical Co in the year 2023?

In the year 2023, Chongqing Lummy Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Chongqing Lummy Pharmaceutical Co pay out the dividend?

The dividends of Chongqing Lummy Pharmaceutical Co are distributed in CNY.

All fundamentals about Chongqing Lummy Pharmaceutical Co

Our stock analysis for Chongqing Lummy Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chongqing Lummy Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.